Kaleido Biosciences, Inc. announced the extension and expansion of its research collaboration with Janssen Biotech, Inc. The collaboration is designed to explore the potential for Microbiome Metabolic Therapies (MMT?) to prevent childhood-onset of atopic, immune and metabolic conditions by promoting healthy function of the gut microbiome. Since the beginning of the collaboration, Kaleido?s proprietary ex vivo screening platform has identified several potential MMTs that support the growth of specific beneficial microbes in the gut microbiome believed to be associated with the development of infant immune systems. Given this progress, the existing agreement with Janssen has subsequently been extended and expanded to optimize the identified MMTs for their ability to support growth of these advantageous microbes and their metabolites. Janssen will fund the additional costs associated with the expanded scope of the collaboration.